ADA
CME Program Email
 

Continuing Medical Education (CME) Information

PROGRAM DESCRIPTION

The benefits of insulin in delaying or even preventing diabetes progression are becoming increasingly recognized, and forthcoming noninvasive formulations of insulin will make it a more acceptable option for diabetes management early in the disease. The incretin therapies may also have the potential of improving pancreatic function and delaying diabetes progression. This is a webcast of a satellite symposium, which was moderated in a “town hall” format, providing a platform for investigators of noninvasive insulin formulations and incretin therapies to discuss the merits of these emerging approaches to the management of diabetes. Audience participation was facilitated through the use of question cards the moderator requested from participants at the beginning of the program; these and other predetermined questions were used as the basis for a discussion of the data.

EDUCATIONAL OBJECTIVES

After participating in this activity, the participants should be better able to

  • Describe emerging approaches for the prevention and treatment of type 2 diabetes
  • Discuss the benefits of incretin therapies in diabetes management
  • Assess the potential of insulin as an early and long-term therapy for diabetes
  • Develop individualized strategies for reducing A1C values while minimizing hypoglycemia and weight gain

TARGET AUDIENCE

Physicians, diabetes educators, and other healthcare professionals who desire information on practical strategies for sustaining glycemic control with novel therapies will find this webcast useful.

ACCREDITATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Tulane University Health Sciences Center and the Council for the Advancement of Diabetes Research and Education (CADRE). Tulane University Health Sciences Center is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION

Tulane University Health Sciences Center designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CADRE and Tulane University Health Sciences Center present this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected because of their recognized expertise.

EDUCATIONAL GRANT

This program is presented in conjunction with CADRE and is supported by an unrestricted educational grant from Pfizer Inc.

FACULTY

Moderator
Derek LeRoith, MD, PhD, FACP
Chief, Division of Endocrinology and Diabetes
Mount Sinai School of Medicine
New York, New York

Faculty Presenters
Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Section on Endocrinology, Diabetes and Metabolic Diseases
Associate Residency Program Director
Department of Internal Medicine
Ochsner Clinic Foundation
New Orleans, Louisiana

William T. Cefalu, MD
Chief of the Nutrition and Chronic Diseases Division
Pennington Biomedical Research Center
Louisiana State University System
Baton Rouge, Louisiana

Julio Rosenstock, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical Center of Dallas
Director, Dallas Diabetes and Endocrine Center
Dallas, Texas

DISCLOSURE

It is the policy of the Center for Continuing Education at Tulane University Health Sciences Center to plan and implement all of its educational activities in accordance with the ACCME's Essential Areas and policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME’s 2004 Standards for Commercial Support, everyone who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all relevant financial relationships with any commercial interests within the past 12 months that create a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity. Individuals with potential for influence or control of CME content include planners and planning committee members, authors, teachers, educational activity directors, educational partners, and others who participate, e.g. facilitators and moderators. This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience.

FACULTY DISCLOSURES

Derek LeRoith, MD, PhD, FACP

Consultant:

Merck & Co., Inc., Pfizer Inc, sanofi-aventis

Speakers’ Bureau:

Merck & Co., Inc., Pfizer Inc, sanofi-aventis

 

 
 
Lawrence Blonde, MD, FACP, FACE

Consultant and/or Honoraria for Presentations:

Abbott Laboratories, Amylin Pharmaceuticals, Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, LifeScan, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, sanofi-aventis, Schering-Plough Corporation, Takeda Pharmaceuticals North America, Inc., Wyeth

Investigator or Subinvestigator in Clinical Trials Sponsored by:

Amylin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, MannKind Corporation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Pharmaceuticals, Inc., Pfizer Inc, sanofi-aventis

Research Grant:

Amylin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, MannKind Corporation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Pharmaceuticals, Inc., Pfizer Inc, sanofi-aventis Speakers’ Bureau: Takeda Pharmaceuticals North America, Inc., Wyeth

Spouse/Partner Financial Relationships

Amylin Pharmaceuticals, Inc., Pfizer Inc

 

 
 
William T. Cefalu, MD

Research Grant:

Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk Pharmaceuticals, Inc., Pfizer Inc

Consultant:

Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc

Speakers’ Bureau:

Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc

 

 
Julio Rosenstock, MD

 

Research Grant:

Amylin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Kos Pharmaceuticals, MannKind Corporation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Pharmaceuticals, Inc., Pfizer Inc, Sankyo Co., Ltd., sanofi-aventis, Takeda Pharmaceuticals North America, Inc.

Consultant/Advisory Board:

Amylin Pharmaceuticals, Inc., Centocor, Inc., GlaxoSmithKline, Johnson & Johnson, Kos Pharmaceuticals, MannKind Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk Pharmaceuticals, Inc., Pfizer Inc, sanofi-aventis, Takeda Pharmaceuticals North America, Inc.

DISCUSSION OF OFF-LABEL USES

Because this course is meant to educate physicians with what is currently in use and what may be available in the future, there may be “off-label” uses discussed in the presentations.

HOW TO OBTAIN CREDIT

Viewers are expected to view and listen to all presentations before applying for CME credit.

Please follow these steps in order to receive a CME credit letter awarding AMA/PRA category 1 credit for viewing the webcast:

  • Read all of the CME information above.
  • View and listen to the complete webcast program.
  • Click on the link to apply for CME credits.
  • Complete and submit (by mail, fax or e-mail) the Verification of Credit and Program Evaluation Forms (in Microsoft Word).
  • Your Record of Credit will be sent to you within 30 days of receipt.

To receive credit, the course must be completed before February 22, 2008.

If you attended the live presentation on June 11, 2006, and received CME credit for this program, you are not eligible for additional credit.

Participation in this activity should be completed in approximately 2.5 hours.

Should you have any CME questions regarding this activity, please contact:
Tulane University
1430 Tulane Ave., TB-51
New Orleans, LA 70112-2699
Tel: 504-988-5466
Fax: 504-988-1779
http://www.cme.tulane.edu
cme@tulane.edu

For technical difficulties, please consult our Technical Instructions.

Release date: February 22, 2007
Expiration date: February 22, 2008

PRIVACY POLICY

It is the policy of Tulane University Health Sciences Center and its Center for Continuing Education (CCE) that personal information for CME activities will be collected only to the extent necessary to provide the service or benefit desired. Only appropriate information will be collected and can be available to be reviewed by the individual providing the information.

ABOUT CADRE

CADRE is a nonprofit organization committed to reducing the devastating complications of type 1 and type 2 diabetes. For information on educational activities offered by CADRE, visit the CADRE Web site at www.cadre-diabetes.org.

Webcast produced by Prous Science
© 2006 Tulane University Health Sciences Center and Council for the Advancement of Diabetes Research and Education (CADRE).